Currently Viewing:
American Society of Clinical Oncology (ASCO) 2017
Dr Barbara McAneny on How the COME HOME Model Helps Cut Hospitalization Rates
June 14, 2017
Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC
June 13, 2017
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
June 06, 2017
Dr Barbara McAneny Outlines Collaboration With ASCO on COME HOME Model
June 05, 2017
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 05, 2017
MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges
June 05, 2017
Dr Craig Portell Highlights New and Exciting Treatments for Non-Hodgkin's Lymphoma
June 05, 2017
Dr Edward Li Discusses the Benefit Biosimilars Can Have in Oncology
June 04, 2017
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
June 04, 2017
Do We Have Adequate Surveillance in Cancer Survivor Care?
June 04, 2017
Dr Basit Chaudhry on Experiences in the Oncology Care Model and Early Indications of Success
June 04, 2017
Dr Scott Ramsey: Value Frameworks Are Moving Toward Harmonization
June 03, 2017
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
June 03, 2017
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
June 03, 2017
Currently Reading
Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers
June 03, 2017
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
May 31, 2017

Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers

Checkpoint inhibitors have begun to revolutionize bladder cancer treatments, but the benefits in prostate cancer are a little less clear at this point, explained Daniel George, MD, of the Duke Cancer Insitute.


Checkpoint inhibitors have begun to revolutionize bladder cancer treatments, but the benefits in prostate cancer are a little less clear at this point, explained Daniel George, MD, of the Duke Cancer Insitute.

Transcript

Can you describe the progress with pembrolizumab, nivolumab, and atezolizumab in prostate and bladder cancer?

With bladder cancer, the checkpoint inhibitors, in particular PD-1 and PD-L1 inhibitors, have really begun to revolutionize this field. Already we have an accelerated approval for atezolizumab in patients previously treated with platinum agents, and most recently for platinum-ineligible patients, based largely on the response rates of 20% to as high as 30% in those populations of patients.

There's an enrichment with patients that are PD-L1 positive in their tumors or in their tumor-infiltrating lymphocytes and that's where these agents may actually be even more effective. Even in the general population we're seeing benefits associated with checkpoint inhibitors, PD-1 strategies in bladder cancer. Most recently published in the New England Journal of Medicine was the pembrolizumab study demonstrating an overall survival benefit associated with pembrolizumab over chemotherapy in patients previously treated with platinum agents.

So, clearly, this field is changing. Where that goes in the future in terms of adjuvant, neo-adjuvant, or first-line treatments remains to be seen, but there's a number of phase 3 studies going on looking at those questions.

In prostate cancer it's a little bit less clear where the PD-1 strategies and PD-L1 strategies will play out. There does seem to be some activity in patients, but it's a little bit hard to predict. It may be that combining with some of the standard of care agents, such as secondary hormonal therapies like enzalutamide or systemic radiation therapies like radium, will demonstrate some benefit. And there's some proof of concept studies going on there. There's also studies looking at it in combination with chemotherapy and with PARP inhibitors, particulary in patients who have DNA damage repair profiles in their tumors. So more to come in prostate cancer.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!